Intellectual Property

Leveraging a Novel Drug Discovery Platform

Cybin is engineering novel, next-generation molecules by selectively modifying tryptamine serotonin receptor agonist (TSRA) scaffolds, leading to the development of new, proprietary active pharmaceutical ingredients (APIs).

Cybin’s proprietary molecules have potential for improved safety, bioavailability, pharmacokinetic profiles and controlled delivery. We aim to fully unlock and optimize the therapeutic benefits of these molecules for patients and providers.

This approach has been integral to the discovery and development of our lead clinical-stage assets, CYB003, our proprietary deuterated psilocin program in development for the treatment of Major Depressive Disorder, and CYB004, our deuterated DMT program in development for the treatment of Generalized Anxiety Disorder.

Advancing Innovative Drug Delivery Systems

Cybin is leveraging efficient delivery systems to provide a direct path to the brain through bypassing first-pass liver metabolism. The goal of this approach is to deliver:

• Fast onset of action;
• Improved dosing control;
• Short duration treatment;
• Low variability;
• Reduced side effects/ favorable, well-tolerated side effect profile; and
• Less invasive / more convenient and patient-friendly dosing methods

Cybin’s proprietary delivery systems are broadly applicable across many compounds, including both deuterated and non-deuterated compounds targeting the 5-HT receptor.

 

 

 

Patents

Cybin has multiple patent filings covering a wide range of novel compounds from different psychedelic classes, including claims to targeted structural modifications to improve the drug pharmacokinetic characteristics and safety profiles without altering their receptor binding.

Cybin’s novel drug delivery platform claims are expected to enable administration of the psychedelic drugs with faster onset of effect, improved bioavailability by way of bypassing the liver metabolism and more efficient dose control for a better patient experience and optimized therapeutic outcomes.

Patents

Cybin has multiple patent filings covering a wide range of novel compounds from different psychedelic classes, including claims to targeted structural modifications to improve the drug pharmacokinetic characteristics and safety profiles without altering their receptor binding.

Cybin’s novel drug delivery platform claims are expected to enable administration of the psychedelic drugs with faster onset of effect, improved bioavailability by way of bypassing the liver metabolism and more efficient dose control for a better patient experience and optimized therapeutic outcomes.

Strong IP with International Coverage 

Cybin has over 70 granted patents and 220 applications pending across
multiple patent families through a combination of internal and external licensing agreements

Cybin is taking a multi-layered approach to securing the intellectual property position for its lead programs CYB003 and CYB004. Cybin has filed multiple patent families around these programs, including claims to composition of matter, formulations, salts and crystalline forms, and methods of treatment. Cybin continues to work to strengthen its intellectual property position for CYB003 and CYB004 through filing new IP based on emerging data from ongoing and future clinical trials and through the protection of additional program IP.

Granted patents in the CYB003 program provide protection until at least 2041. Cybin has been granted a composition of matter patent from the USPTO that covers composition of matter claims on the NCE-eligible CYB004 active molecule until at least 2041. The multilayered patent strategy includes:

  • Broad formulations
  • Salt / crystalline forms
  • Formulations with stabilizer/solubilizer
  • MOT supported by highly positive clinical data

Granted patents in the CYB004 program provide protection until at least 2041. The multi-layered strategy includes:
Composition of Matter
Broad formulations
Salt / crystalline forms
MOT supported by positive clinical data

PROGRAM
  • PROVISIONAL
  • INTERNATIONAL (PCT)
  • NATIONAL STAGE
  • PATENT GRANT
CYB002

Amorphous psilocybin

INTERNATIONAL (PCT)
CYB003

Psilocybin analogs

INTERNATIONAL (PCT)
CYB004

Proprietary Tryptamine derivatives

PATENT GRANT
CYB004

Tryptamines compositions

PROVISIONAL
CYB004

Inhalation delivery methods

INTERNATIONAL (PCT)
CYB004

Combination drug therapies

INTERNATIONAL (PCT)
CYB005

Phenethylamine class A

INTERNATIONAL (PCT)
CYB005

Phenethylamine class B

INTERNATIONAL (PCT)
CYB005

Phenethylamine class C

PROVISIONAL
CYB005

Phenethylamine class D

PROVISIONAL